Your Shopping Cart Is Empty
| Report Code: A13035 | Aug 2021 | Pages: 159 | ||
| Tables: 68 | Charts: 40 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Asia-pacific Fertility Services Market
Request Now !The Asia-Pacific fertility services market size was valued at $4,529.06 million in 2020, and is expected to reach $20,492.95 million by 2030, registering a CAGR of 15.5% from 2021 to 2030.
The COVID-19 pandemic has affected the Asia-Pacific fertility services market. Most fertility clinics across the region have stopped undertaking new cases of infertility treatment for the next few months, till the condition seems to be under control. Moreover, egg donation treatments are canceled and frozen embryos are preserved for later use. Several ongoing pregnancies have been struggling, owing to the disruption caused by COVID-19 pandemic. Thus, pandemic impacts the fertility services market and in turn limit the adoption of fertility services in the region.
Fertility services support the treatments used to cure infertility. These services often include techniques like artificial insemination, in vitro fertilization (IVF), surrogacy, and others. Infertility, in general, is defined as not being able to conceive after a year of unprotected coitus. It can occur in both males and females of child-bearing age. In men, infertility is caused by different factors which are generally analyzed by a semen analysis. Some of the factors which are highly likely to cause male infertility include trauma to the testes, varicoceles (a condition in which the testicle veins are large causing overheat. This affects the size of the sperms), use of certain medications, and medical conditions like diabetes, autoimmune disorders, and cystic fibrosis. On the other hand, in females, infertility is often caused due to disruptions of ovarian function with age. However, other causes might include polycystic ovarian syndrome (PCOS), diminished ovarian reserve, functional hypothalamic amenorrhea (FHA), and premature ovarian insufficiency (POI).
Rise in awareness regarding different infertility treatments, decline in fertility rate, technological advancements made in the field of assisted reproductive technologies (ART), and the growth in fertility clinics in the Asia-Pacific region are likely to boost the growth of the Asia-Pacific fertility services market during the forecast period. However, the high cost associated with these infertility treatments is one of the factors that can impede the market growth. Certain factors which can increase the risk of infertility include age, use of marijuana, excessive alcohol use, exposure to testosterone, exposure to radiation, and extreme weight gain or weight loss. About 1 in 6 couples have fertility problems when the woman is 35 and older. Aging is known to decrease fertility because older women have fewer eggs. In addition, aging also increases the chances of a miscarriage. The rise in awareness regarding surrogacy and egg/sperm donation has increased the growth of the market. Furthermore, the rise in the median age of first-time motherhood is also fuelling the market growth as women now tend to focus on their career first before they choose to become a mother for the first time. With a sedentary and fast-paced lifestyle, most women tend to suffer from different gynecological conditions which further reduce their chances of conceiving naturally and augment the growth of the Asia-Pacific fertility services market.
The COVID-19 outbreak that started from Wuhan city of China has now spread globally. Almost every nation is dealing with the outbreak. Most markets are experiencing a decline, owing to the outbreak. This also includes the fertility services market. The fertility services market is negatively impacted by the pandemic. In addition, most fertility clinics across the globe have stopped undertaking new cases of infertility treatment for the next few months, till the condition seems to be under control.
For instance, on March 17, 2020, the American Society for Reproductive Medicine (ASRM) issued certain recommendations that included not initiating new cycles of assisted ovulation, intrauterine inseminations (IUIs), in vitro fertilization (IVF), or “non-urgent” egg freezing. Some women have postponed their fertility consultations, whereas others have delayed their dates of embryo transfer until the pandemic situation ends and life comes back to normal.
In the ongoing COVID-19 situation, gynecologists are managing antenatal care during pregnancy through online video sessions to limit exposure to the outside world. However, asymptomatic patients from the U.S. were able to continue with their initial treatment plan. Most oocyte donation treatments and all embryo transferences from patients follow the recommended “freeze-all” strategy and later embryo transfer are being performed under controlled conditions.
Moreover, egg donation treatments are canceled, and frozen embryos are preserved for later use. Furthermore, many ongoing pregnancies have been struggling, owing to the disruption caused by COVID-19 pandemic. The patient treatment schedule has been changed, owing to which the patients have to face huge emotional dissatisfaction and uncertainty.
The ongoing pregnancies by IVF are also struggling for necessary scans and medicines. Thus, factors mentioned above impact the fertility services market and in turn limit the adoption of fertility services in the developed markets.
The Asia-Pacific fertility services market is classified into procedure, service, end user, and country. By procedure, the market is divided into IVF with intracytoplasmic sperm injection (ICSI), surrogacy, IVF without ICSI, intrauterine insemination (IUI), surrogacy, and others. By service, it is categorized into fresh non-donor, frozen non-donor, egg & embryo banking, fresh donor, and frozen donor. By end user, it is classified into fertility clinics, hospitals, surgical centers, and clinical research institutes. On the basis of country, the market is analyzed across Japan, India, China, Australia, South Korea, Thailand, Malaysia, Singapore, New Zealand, Philippines, Indonesia, and the rest of Asia-Pacific.
By fertility services market analysis, the IVF with ICSI segment accounted for half of the market share in the fertility services market in 2020. This segment is expected to exhibit a prominent growth rate, owing to some key factors such as higher success rates associated with ICSI-IVF in case of poor sperm morphology, poor sperm motility, low sperm count, and others. Moreover, the rapid increase in the infertility rate is one of the major factors that drive the growth of the fertility services market.
By procedure, the IVF with ICSI segment accounted for the largest market share in 2020. This segment is expected to exhibit a prominent growth rate, attributed to the fact that it has revolutionized male infertility treatment, as it requires a smaller number of sperms that are penetrated into the egg with the help of injection technique.
Asia-Pacific presents lucrative opportunities for key players operating in the fertility services market, owing to the increase in accessibility and availability of healthcare facilities and a rise in healthcare and research expenditure. This region is anticipated to experience rapid market growth due to economic development. Moreover, the fertility services in countries such as India are cheaper as compared to the developed countries such as the U.S., Canada, and others; thereby, fueling the market growth in this region. The growth of the fertility services market is supplemented by a surge in the adoption of fertility procedures and a rise in fertility tourism. China dominated the Asia-Pacific fertility services market in 2020 and is expected to register the highest CAGR during the forecast period. This is attributed to increase in awareness and acceptance within the country for adopting fertility services.
The key players operating in the Asia-Pacific fertility services market include Apollo Hospitals Enterprise Ltd, CooperSurgical, Inc., City Fertility, ESCO Life Sciences Group, Fertility Associates Limited, Genea Limited, Medicover Group, Monash IVF Group Limited, Thermo Fisher Scientific Inc., and Virtus Health.
Key Benefits For Stakeholders
Key Market Segments
By Procedure
By Service
By End User
By Country
List of key players profiled in the report
Asia-Pacific Fertility Services Market Report Highlights
| Aspects | Details |
|---|---|
| By Procedure |
|
| By Service |
|
| By End User |
|
| By Country |
|
| Key Market Players | ESCO LIFE SCIENCES GROUP, MONASH IVF GROUP LIMITED, MEDICOVER GROUP (MEDICOVER FERTILITY and FIRST EGG BANK), THERMO FISHER SCIENTIFIC INC., GENEA LIMITED, CITY FERTILITY, VIRTUS HEALTH, COOPERSURGICAL, INC., FERTILITY ASSOCIATES LIMITED, APOLLO HOSPITALS ENTERPRISE LTD. |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Continuous decline in fertility rates
3.4.1.2.Delayed pregnancies in women
3.4.1.3.Technological advancements with respect to fertility treatment
3.4.2.Restraints
3.4.2.1.High treatment costs of ARTs in emerging countries
3.4.2.2.Inadequate reimbursement policies
3.4.3.Opportunity
3.4.3.1.Rise in fertility tourism
3.5.COVID-19 impact on the fertility services market
CHAPTER 4:FERTILITY SERVICES MARKET, BY PROCEDURE
4.1.Overview
4.1.1.Market size and forecast
4.2.IVF with ICSI
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.3.IUI
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.4.IVF without ICSI
4.4.1.Key market trends growth factors, and opportunities
4.4.2.Market size and forecast
4.5.Surrogacy
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.6.Others
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
CHAPTER 5:FERTILITY SERVICES MARKET, BY SERVICE
5.1.Overview
5.1.1.Market size and forecast
5.2.Fresh non-donor
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast
5.3.Frozen non-donor
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast
5.4.Egg & embryo banking
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast
5.5.Fresh donor
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast
5.6.Frozen donor
5.6.1.Key market trends, growth factors, and opportunities
5.6.2.Market size and forecast
CHAPTER 6:FERTILITY SERVICES MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Fertility clinics
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast
6.3.Hospitals
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast
6.4.Surgical centers
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast
6.5.Clinical research institutes
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast
CHAPTER 7:ASIA-PACIFIC FERTILITY SERVICES MARKET, BY COUNTRY
7.1.Overview
7.1.1.Market size and forecast
7.2.Japan
7.2.1.Market size and forecast, by procedure
7.2.2.Market size and forecast, by service
7.2.3.Market size and forecast, by end user
7.3.India
7.3.1.Market size and forecast, by procedure
7.3.2.Market size and forecast, by service
7.3.3.Market size and forecast, by end user
7.4.China
7.4.1.Market size and forecast, by procedure
7.4.2.Market size and forecast, by service
7.4.3.Market size and forecast, by end user
7.5.Australia
7.5.1.Market size and forecast, by procedure
7.5.2.Market size and forecast, by service
7.5.3.Market size and forecast, by end user
7.6.South Korea
7.6.1.Market size and forecast, by procedure
7.6.2.Market size and forecast, by service
7.6.3.Market size and forecast, by end user
7.7.Thailand
7.7.1.Market size and forecast, by procedure
7.7.2.Market size and forecast, by service
7.7.3.Market size and forecast, by end user
7.8.Malaysia
7.8.1.Market size and forecast, by procedure
7.8.2.Market size and forecast, by service
7.8.3.Market size and forecast, by end user
7.9.Singapore
7.9.1.Market size and forecast, by procedure
7.9.2.Market size and forecast, by service
7.9.3.Market size and forecast, by end user
7.10.New Zealand
7.10.1.Market size and forecast, by procedure
7.10.2.Market size and forecast, by service
7.10.3.Market size and forecast, by end user
7.11.Philippines
7.11.1.Market size and forecast, by procedure
7.11.2.Market size and forecast, by service
7.11.3.Market size and forecast, by end user
7.12.Indonesia
7.12.1.Market size and forecast, by procedure
7.12.2.Market size and forecast, by service
7.12.3.Market size and forecast, by end user
7.13.Rest of Asia-Pacific
7.13.1.Market size and forecast, by procedure
7.13.2.Market size and forecast, by service
7.13.3.Market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.APOLLO HOSPITALS ENTERPRISE LTD.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.CITY FERTILITY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments
8.3.COOPERSURGICAL, INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.ESCO LIFE SCIENCES GROUP
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments
8.5.FERTILITY ASSOCIATES LIMITED
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.6.GENEA LIMITED
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Key strategic moves and developments
8.7.MEDICOVER GROUP (MEDICOVER FERTILITY and FIRST EGG BANK)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.MONASH IVF GROUP LIMITED
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.THERMO FISHER SCIENTIFIC INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business Performance
8.9.6.Key strategic moves and developments
8.10.VIRTUS HEALTH
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.ASIA-PACIFIC FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 02.ASIA-PACIFIC FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 03.ASIA-PACIFIC FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 04.ASIA-PACIFIC FERTILITY SERVICES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 05.JAPAN FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 06.JAPAN FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 07.JAPAN FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 08.INDIA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 09.INDIA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 10.INDIA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 11.CHINA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 12.CHINA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 13.CHINA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14.AUSTRALIA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 15.AUSTRALIA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 16.AUSTRALIA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 17.SOUTH KOREA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 18.SOUTH KOREA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 19.SOUTH KOREA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 20.THAILAND FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 21.THAILAND FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 22.THAILAND FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 23.MALAYSIA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 24.MALAYSIA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 25.MALAYSIA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 26.SINGAPORE FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 27.SINGAPORE FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 28.SINGAPORE FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 29.NEW ZEALAND FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 30.NEW ZEALAND FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 31.NEW ZEALAND FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 32.PHILIPPINES FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 33.PHILIPPINES FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 34.PHILIPPINES FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 35.INDONESIA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 36.INDONESIA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 37.INDONESIA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 38.REST OF ASIA-PACIFIC FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 39.REST OF ASIA-PACIFIC FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 40.REST OF ASIA-PACIFIC FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 41.APOLLO HOSPITALS: COMPANY SNAPSHOT
TABLE 42.APOLLO HOSPITALS: OPERATING SEGMENTS
TABLE 43.APOLLO HOSPITALS: PRODUCT PORTFOLIO
TABLE 44.CITY FERTILITY: COMPANY SNAPSHOT
TABLE 45.CITY FERTILITY: PRODUCT PORTFOLIO
TABLE 46.COOPERSURGICAL: COMPANY SNAPSHOT
TABLE 47.COOPERSURGICAL: OPERATING SEGMENTS
TABLE 48.COOPERSURGICAL: PRODUCT PORTFOLIO
TABLE 49.ESCO: COMPANY SNAPSHOT
TABLE 50.ESCO: OPERATING SEGMENTS
TABLE 51.ESCO: PRODUCT PORTFOLIO
TABLE 52.FERTILITY ASSOCIATES: COMPANY SNAPSHOT
TABLE 53.FERTILITY ASSOCIATES: OPERATING SEGMENTS
TABLE 54.FERTILITY ASSOCIATES: PRODUCT PORTFOLIO
TABLE 55.GENEA LIMITED: COMPANY SNAPSHOT
TABLE 56.GENEA LIMITED: OPERATING SEGMENTS
TABLE 57.GENEA LIMITED: PRODUCT PORTFOLIO
TABLE 58.MEDICOVER: COMPANY SNAPSHOT
TABLE 59.MEDICOVER: OPERATING SEGMENTS
TABLE 60.MEDICOVER: PRODUCT PORTFOLIO
TABLE 61.MVF: COMPANY SNAPSHOT
TABLE 62.MVF: PRODUCT PORTFOLIO
TABLE 63.THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 64.THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 65.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 66.VIRTUS HEALTH: COMPANY SNAPSHOT
TABLE 67.VIRTUS HEALTH: OPERATING SEGMENTS
TABLE 68.VIRTUS HEALTH: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.FERTILITY SERVICES MARKET: MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.HIGH BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH THREAT OF SUBSTITUTION
FIGURE 09.HIGH THREAT OF NEW ENTRANT
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.MARKET DYNAMICS
FIGURE 12.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR IVF WITH ICSI, 2020-2030 ($MILLION)
FIGURE 13.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR IUI, 2020-2030 ($MILLION)
FIGURE 14.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR IVF WITHOUT ICSI, 2020-2030 ($MILLION)
FIGURE 15.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR SURROGACY, 2020-2030 ($MILLION)
FIGURE 16.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR OTHERS, 2020-2030 ($MILLION)
FIGURE 17.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FRESH NON-DONOR, 2020-2030 ($MILLION)
FIGURE 18.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FROZEN NON-DONOR, 2020-2030 ($MILLION)
FIGURE 19.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR EGG AND EMBRYO BANKING, 2020-2030 ($MILLION)
FIGURE 20.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FRESH DONOR, 2020-2030 ($MILLION)
FIGURE 21.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FROZEN DONOR, 2020-2030 ($MILLION)
FIGURE 22.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FERTILITY CLINICS, 2020-2030 ($MILLION)
FIGURE 23.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR HOSPITALS, 2020-2030 ($MILLION)
FIGURE 24.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR SURGICAL CENTERS, 2020-2030 ($MILLION)
FIGURE 25.ASIA-PACIFIC FERTILITY SERVICES MARKET FOR CLINICAL RESEARCH INSTITUTES, 2020-2030 ($MILLION)
FIGURE 26.APOLLO HOSPITALS: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.APOLLO HOSPITALS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28.COOPERSURGICAL: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.COOPERSURGICAL: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.MEDICOVER: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.MEDICOVER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.MEDICOVER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.MVF: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.MVF: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.THERMO FISHER SCIENTIFIC: REVENUE, 2018–2020 ($MILLION)
FIGURE 36.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.VIRTUS HEALTH: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.VIRTUS HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.VIRTUS HEALTH: REVENUE SHARE BY REGION, 2020 (%)
This section provides the opinions of the top-level CXOs in the Asia-Pacific fertility services industry. According to the CXOs, fertility services include assisted reproductive technology procedures undertaken by couples who cannot conceive naturally.
These services are availed to treat infertility. These services often include techniques like artificial insemination, in vitro fertilization (IVF), surrogacy, and more. Out of all these techniques, IVF is the one used and chosen most widely. In IVF the sperm is combined with the egg in vitro. The process involves the stimulation and monitoring of the woman's ovulation process, removing the eggs (ova) from the ovaries, and letting the sperm fertilize them in a laboratory's culture medium. IVF is mostly prescribed to women with blocked or missing oviducts (fallopian tubes). Some other causes that cause female infertility such as endometriosis, fibroids, polycystic ovary syndrome (PCOS), and cervical problems might also require intervention with IVF.
According to the CXOs, the fertility services market is anticipated to witness considerable growth in the future, owing to the emerging trend of delayed first-time pregnancy among women, rise in prevalence of infertility in both males and females, technological advancements in assisted reproductive technology (ART) procedures, and increased incidence of sperms and eggs donations.
Furthermore, the increase in the prevalence of IVF procedures and a rise in awareness regarding surrogacy, egg freezing, and egg banks are expected to fuel the growth of the market. However, insufficient reimbursement policies for couples opting for fertility procedures and stringent regulations in some countries against fertility procedures for single patients and members from the LGBT community are some of the factors that can impede market growth during the forecast period.
However, emerging markets such as India are offering fertility procedures for single parents and same-sex couples which might offer lucrative growth opportunities for market expansion in the Asia-Pacific region.
A. The total market value of fertility services market was $4,529.06 million in 2020.
A. The forcast period for fertility services market is 2021 to 2030
A. The market value of fertility services market in 2030 will be $20,492.95 million.
A. The base year is 2020 for the fertility services market
A. Top companies such as Apollo Hospitals Enterprise Ltd., CooperSurgical, Inc., Fertility Associates Limited, Genea Limited and others held a high market position in 2020. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. In procedure segment IVF with ICSI is the most influencing segment. This segment is expected to exhibit a prominent growth rate, owing to some key factors such as higher success rates associated with ICSI-IVF in case of poor sperm morphology, poor sperm motility, low sperm count, and others. In addition, rise in awareness regarding IVF with ICSI also have a positive effect on the market.
A. The major factor that fuels the growth of the Asia-Pacific fertility services market includes continuous decline in fertility rates, trend of delayed pregnancy in women, and technological advancements with respect to fertility treatment is expected growth of the market. On the contrary, developing economies and untapped markets are expected to provide lucrative opportunities for the market growth in the future.
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the emerging countries. This is due to the fertility services in countries such as India are cheaper as compare to the developed countries such as the U.S., Canada, and others; thereby, fueling the market growth of fertility services in this region, development in healthcare infrastructure, and rise in number of hospitals & research centers equipped with advanced medical facilities.
A. Infertility is a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse
A. IVF with intracytoplasmic sperm injection (ICSI), surrogacy, IVF without ICSI, intrauterine insemination (IUI), surrogacy, and others.
Start reading instantly.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report